Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 19 2026
0mins
Should l Buy ISRG?
Source: NASDAQ.COM
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 469.210
Low
575.00
Averages
637.32
High
740.00
Current: 469.210
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical Set to Announce Q1 Earnings on April 21
- Earnings Expectations: Intuitive Surgical is set to announce its Q1 earnings on April 21, with analysts forecasting an EPS of $2.11, reflecting a 16.6% year-over-year increase, and revenue of $2.62 billion, up 16.4%, indicating sustained profitability and growth potential.
- Historical Performance: Over the past two years, Intuitive Surgical has exceeded EPS and revenue estimates 100% of the time, showcasing its financial stability and market confidence.
- Valuation Challenges: Despite strong fundamentals, Seeking Alpha's Quant model rates Intuitive Surgical as a Hold due to its high P/E ratio of 63 compared to a historical average of 53.5, highlighting investment risks associated with elevated valuations.
- Market Leadership: As the leader in robotic-assisted surgery, Intuitive Surgical reported an 18% increase in procedures and a 19% revenue growth to $2.87 billion in Q4, with robust cash flow and high margins providing a solid foundation for future growth despite recent technical weaknesses.
See More
Intuitive Surgical Continues Robust Growth
- Market Value Insight: Intuitive Surgical boasts a market value nearing $163 billion, and while its shares are currently priced below average, it maintains a dominant position in the robotic surgical systems sector, indicating strong market presence and future growth potential.
- Investment Return Outlook: Investing $1,000 monthly with an assumed annual growth rate of 12% could yield $864,629 after 20 years, suggesting the company has the potential to provide substantial retirement income for investors, especially if it begins paying dividends in the future.
- Valuation Metrics: The current forward P/E ratio stands at 46, which, although high, is lower than the five-year average of 57, indicating relative investment attractiveness, while the price-to-sales ratio of 16.5 is also below the five-year average of 18.4.
- Long-Term Holding Recommendation: Despite potential short-term price fluctuations, purchasing Intuitive Surgical shares now could yield favorable returns for long-term investors, with a strategy of gradually building a position to mitigate risk.
See More
American Airlines Rejects United Airlines Merger Proposal as Anti-Competitive
- Merger Proposal Rejected: American Airlines shares fell in pre-market trading on Monday after firmly rejecting United Airlines' merger proposal, citing significant antitrust hurdles that would give the combined entity a 40% domestic market share, negatively impacting competition.
- Regulatory Scrutiny Pressure: Legal experts suggest that a merger would face unprecedented scrutiny, as the 'Big Four' airlines already control 80% of U.S. capacity, potentially dominating key hubs like Chicago and Dallas by up to 70%.
- Strategic Shift Possible: Despite the rejection, United Airlines may pivot towards smaller acquisitions or asset divestitures to satisfy an administration favoring landmark deals while avoiding concerns over consumer pricing monopolies, thereby maintaining competitive positioning.
- Market Reaction: Following the merger proposal rejection, American Airlines' stock dropped 3.13% and United Airlines' stock fell 3.04%, reflecting market pessimism regarding the merger prospects and potentially influencing future strategic decisions for both companies.
See More
Tesla Set to Report Q1 Earnings Amid Market Surge
- Tesla Earnings Outlook: Tesla is set to report its Q1 fiscal 2026 earnings on Wednesday, with the stock down 11% year-to-date; however, it has shown recovery in April as CEO Elon Musk garners attention for the upcoming SpaceX IPO, and analysts predict profit growth despite vehicle deliveries of 358,000 falling short of the 370,000 expected.
- Terafab Project Acceleration: Musk is urging potential suppliers to expedite the Terafab AI chip-making project, which is estimated to cost over $25 billion and aims to achieve an annual computing capacity of one terawatt, highlighting Tesla's ambitions in the AI sector.
- Market Performance Surge: Despite uncertainties surrounding dealings with Iran, both the S&P 500 and Nasdaq reached new all-time highs, rising 4.5% and 6.8% respectively, while the Dow Jones increased by 3.2%, indicating a robust market recovery.
- Oil Price Impact: Following the U.S. Navy's seizure of an Iranian-flagged ship, benchmark crude prices surged over 6%, with West Texas Intermediate surpassing $88 and Brent crude exceeding $95, which could influence market sentiment.
See More
Intuitive Surgical: Future Investment Potential
- Market Value Growth: Intuitive Surgical boasts a market value nearing $163 billion, and while it currently does not pay dividends, its share repurchases enhance shareholder value, demonstrating a commitment to returns.
- Global Impact: Over 20.4 million patients have undergone procedures with Intuitive systems, which are utilized in more than 70 countries, with over 12,000 systems installed, underscoring its leadership in the robotic surgery sector.
- Strong Financial Performance: The company's latest earnings report revealed a 19% year-over-year revenue increase to $2.9 billion, with procedures growing by 18%, and Ion system procedures surging by 44%, indicating robust product demand.
- Investment Outlook Analysis: Despite a current P/E ratio of 46, below the five-year average of 57, if investors contribute $1,000 monthly with an assumed 12% annual growth, they could accumulate $864,629 in 20 years, highlighting the potential of long-term investments.
See More
Investment Opportunities in Healthcare Stocks
- Market Volatility Impact: The stock market has faced increased volatility recently, with the S&P 500 shifting from gains to losses; although the market has rebounded, many stocks remain at lower valuation levels, reflecting ongoing investor concerns about the economy and interest rate policies.
- Da Vinci Surgical Robot: Intuitive Surgical's Da Vinci surgical robot, priced over $1 million, offers hospitals various options and boasts 150 design innovations and 10,000 times the computing power of its predecessor, helping the company maintain market leadership with a 19% revenue growth in the last quarter.
- Abbott Laboratories Diversification: Abbott Laboratories achieves diversification through its four business units—medical devices, diagnostics, pharmaceuticals, and nutrition—ensuring that when one segment faces challenges, others can provide support, enhancing overall company safety.
- Attractive Dividend Growth: As a 'Dividend King' that has raised its dividend for 50 consecutive years, Abbott's current stock price at 17 times forward earnings, down from 22 times in early 2026, makes it a compelling healthcare stock to invest in following recent market turbulence.
See More
Intuitive Surgical Set to Announce Q1 Earnings on April 21
- Earnings Expectations: Intuitive Surgical is set to announce its Q1 earnings on April 21, with analysts forecasting an EPS of $2.11, reflecting a 16.6% year-over-year increase, and revenue of $2.62 billion, up 16.4%, indicating sustained profitability and growth potential.
- Historical Performance: Over the past two years, Intuitive Surgical has exceeded EPS and revenue estimates 100% of the time, showcasing its financial stability and market confidence.
- Valuation Challenges: Despite strong fundamentals, Seeking Alpha's Quant model rates Intuitive Surgical as a Hold due to its high P/E ratio of 63 compared to a historical average of 53.5, highlighting investment risks associated with elevated valuations.
- Market Leadership: As the leader in robotic-assisted surgery, Intuitive Surgical reported an 18% increase in procedures and a 19% revenue growth to $2.87 billion in Q4, with robust cash flow and high margins providing a solid foundation for future growth despite recent technical weaknesses.
See More
Intuitive Surgical Continues Robust Growth
- Market Value Insight: Intuitive Surgical boasts a market value nearing $163 billion, and while its shares are currently priced below average, it maintains a dominant position in the robotic surgical systems sector, indicating strong market presence and future growth potential.
- Investment Return Outlook: Investing $1,000 monthly with an assumed annual growth rate of 12% could yield $864,629 after 20 years, suggesting the company has the potential to provide substantial retirement income for investors, especially if it begins paying dividends in the future.
- Valuation Metrics: The current forward P/E ratio stands at 46, which, although high, is lower than the five-year average of 57, indicating relative investment attractiveness, while the price-to-sales ratio of 16.5 is also below the five-year average of 18.4.
- Long-Term Holding Recommendation: Despite potential short-term price fluctuations, purchasing Intuitive Surgical shares now could yield favorable returns for long-term investors, with a strategy of gradually building a position to mitigate risk.
See More
American Airlines Rejects United Airlines Merger Proposal as Anti-Competitive
- Merger Proposal Rejected: American Airlines shares fell in pre-market trading on Monday after firmly rejecting United Airlines' merger proposal, citing significant antitrust hurdles that would give the combined entity a 40% domestic market share, negatively impacting competition.
- Regulatory Scrutiny Pressure: Legal experts suggest that a merger would face unprecedented scrutiny, as the 'Big Four' airlines already control 80% of U.S. capacity, potentially dominating key hubs like Chicago and Dallas by up to 70%.
- Strategic Shift Possible: Despite the rejection, United Airlines may pivot towards smaller acquisitions or asset divestitures to satisfy an administration favoring landmark deals while avoiding concerns over consumer pricing monopolies, thereby maintaining competitive positioning.
- Market Reaction: Following the merger proposal rejection, American Airlines' stock dropped 3.13% and United Airlines' stock fell 3.04%, reflecting market pessimism regarding the merger prospects and potentially influencing future strategic decisions for both companies.
See More
Tesla Set to Report Q1 Earnings Amid Market Surge
- Tesla Earnings Outlook: Tesla is set to report its Q1 fiscal 2026 earnings on Wednesday, with the stock down 11% year-to-date; however, it has shown recovery in April as CEO Elon Musk garners attention for the upcoming SpaceX IPO, and analysts predict profit growth despite vehicle deliveries of 358,000 falling short of the 370,000 expected.
- Terafab Project Acceleration: Musk is urging potential suppliers to expedite the Terafab AI chip-making project, which is estimated to cost over $25 billion and aims to achieve an annual computing capacity of one terawatt, highlighting Tesla's ambitions in the AI sector.
- Market Performance Surge: Despite uncertainties surrounding dealings with Iran, both the S&P 500 and Nasdaq reached new all-time highs, rising 4.5% and 6.8% respectively, while the Dow Jones increased by 3.2%, indicating a robust market recovery.
- Oil Price Impact: Following the U.S. Navy's seizure of an Iranian-flagged ship, benchmark crude prices surged over 6%, with West Texas Intermediate surpassing $88 and Brent crude exceeding $95, which could influence market sentiment.
See More
Intuitive Surgical: Future Investment Potential
- Market Value Growth: Intuitive Surgical boasts a market value nearing $163 billion, and while it currently does not pay dividends, its share repurchases enhance shareholder value, demonstrating a commitment to returns.
- Global Impact: Over 20.4 million patients have undergone procedures with Intuitive systems, which are utilized in more than 70 countries, with over 12,000 systems installed, underscoring its leadership in the robotic surgery sector.
- Strong Financial Performance: The company's latest earnings report revealed a 19% year-over-year revenue increase to $2.9 billion, with procedures growing by 18%, and Ion system procedures surging by 44%, indicating robust product demand.
- Investment Outlook Analysis: Despite a current P/E ratio of 46, below the five-year average of 57, if investors contribute $1,000 monthly with an assumed 12% annual growth, they could accumulate $864,629 in 20 years, highlighting the potential of long-term investments.
See More
Investment Opportunities in Healthcare Stocks
- Market Volatility Impact: The stock market has faced increased volatility recently, with the S&P 500 shifting from gains to losses; although the market has rebounded, many stocks remain at lower valuation levels, reflecting ongoing investor concerns about the economy and interest rate policies.
- Da Vinci Surgical Robot: Intuitive Surgical's Da Vinci surgical robot, priced over $1 million, offers hospitals various options and boasts 150 design innovations and 10,000 times the computing power of its predecessor, helping the company maintain market leadership with a 19% revenue growth in the last quarter.
- Abbott Laboratories Diversification: Abbott Laboratories achieves diversification through its four business units—medical devices, diagnostics, pharmaceuticals, and nutrition—ensuring that when one segment faces challenges, others can provide support, enhancing overall company safety.
- Attractive Dividend Growth: As a 'Dividend King' that has raised its dividend for 50 consecutive years, Abbott's current stock price at 17 times forward earnings, down from 22 times in early 2026, makes it a compelling healthcare stock to invest in following recent market turbulence.
See More
